
Empowered Patient Podcast
Empowered Patient Podcast with Karen Jagoda is a window into the latest innovations in digital health, the changing dynamic between doctors and patients, and the emergence of precision medicine. The show covers such topics as aging in place, innovative uses for wearables and sensors, advances in clinical research, applied genetics, drug development, and challenges for connected health entrepreneurs.
Latest episodes

May 8, 2025 • 20min
Care Orchestration Optimizing Provider Capacity and Access to Care with Dr. Sonja Tarrago DexCare
Dr. Sonja Tarrago, head of Physician Strategy and Engagement at DexCare, has created a care orchestration platform to help health systems improve patient access to care, direct patients to the proper care, and optimize provider capacity. DexCare solutions have enabled health systems to treat more patients with existing resources, increase new patient acquisition, and reduce time to care. This platform reduces long wait times, provides real-time online scheduling, and matches patient demand with provider availability. Sonja explains, "DexCare is a care orchestration platform used by leading health systems to help manage the supply and demand of healthcare. That means that our platform helps health systems get discovered at the point of search. So, where patients are searching for care, we know that's typically Google, and then we navigate patients to the best fit care. So we do that while optimizing provider capacity and resources in real time. So, as we talk about our customers, we think that first of all, we need to acknowledge that healthcare is in crisis right now." "In addition to making care more discoverable, we're using data to help direct our patients to the right care based on what they're looking for. This makes sure that the patients are getting connected to the right resources within the health systems that we work with, and we're helping to reduce bottlenecks and improve efficiencies within the health system." "So we need to help patients find care, not find a doctor. In addition to that, I think another gap is that patients have limited access to real-time online scheduling. And by that, I don't mean a form that a patient fills out and waits for someone to get back to them. I mean a real-time slot that patients can book into." #DexCare #CareOrchestration #DigitalHealth #CareOptimization dexcare.com Download the transcript here

May 7, 2025 • 21min
Using AI to Tackle Demands of the Clinical Inbox Reducing Doctor Burnout with David Norris Affineon
David Norris, Founder and CEO of Affineon Health Inc., recognizes the significant problem of provider burnout, which is primarily caused by the time doctors spend on administrative tasks rather than with the patient. Affineon's AI-powered solution aims to address this by automating the review of the provider's inbox and reducing their cognitive load. The inboxes are filled with lab results, pharmacy messages, and other tasks that need review. This approach enables doctors to focus on the required actions quickly. David explains, "We're attacking one of the biggest problems providers often complain about: the inbox. And this is their clinical inbox, not their email inbox like you and I have. The clinical inbox is typically filled with hundreds of things that come in daily. For a PCP, this can often include things like lab results. So you go to your doctor for your annual wellness visit, and they order five to 10 different labs, which come into their inbox the next day. If you're seeing 20 patients a day, that's hundreds of results, plus you're getting prescription renewal requests from the pharmacies, you're getting patient messages. The provider, while trying to stay focused on seeing 20 patients a day and keeping their focus on those patients, they're now literally trying to squeeze a little inbox time in before and after patients." "Affineon has introduced an AI inbox that integrates directly into the electronic health record system. We do exactly what you would do if you hired an assistant in the medical terminology, triage your inbox, which is to handle everything they can handle. The provider focuses on the most critical things. So we're using an AI agent to do that, and unlike a human, which would be very costly to do this, our solution costs $2.50 a day. So about half a cup of coffee. So, for a provider to now have the ability to have an assistant triage their inbox every day and to help them by reducing their daily inbox volume by up to 50%-60%, that's pretty incredible. And before AI, that wasn't possible." #Affineon #MedAI #ProviderBurnout #AIInbox affineon.com Download the transcript here

May 6, 2025 • 18min
Using Pulse Electric Field and Direct Tumor Injections to Target Advanced Cancers with Dr. Jason Williams The Williams Cancer Institute
Dr. Jason Williams, President and Director of Interventional Oncology and Immunotherapy at the Williams Cancer Institute, uses a combination of Pulse Electric Field technology to ablate tumors and direct injection of immunotherapy drugs into the tumor to stimulate the immune system. This approach can be used in conjunction with traditional cancer treatments and has fewer side effects than standard immunotherapy. This method is part of the broader trend in cancer research to provide a more targeted approach to treating tumors. Jason explains, "Our big focus is going to the tumor itself, so we do treatments directly at the tumor, and we do a combination of things. We do things that will be considered ablation where we're using different technologies or energies — I'll explain — particularly, we use one called Pulse Electric Field (PEF), which kills the tumor by essentially shocking it, and that kills it in a way that actually makes the immune system see it better. You're not trying to kill all of the tumor, you're trying to kill pieces for the immune system. Then we inject drugs into that area of the tumor, particularly immunotherapy drugs, but it can be other drugs as well, and just really taking the fight to the cancer right in the tumor." "I think that our mistake in cancer treatments is that we're not addressing the tumors directly. I mean, it's one thing to expect that you're going to take a drug orally or intravenously and that it's going to arrive and make it to the cancer cells. Still, the other way is to go right into it, putting the drugs there, and particularly with immunotherapies, where you want to attract the immune system to it. You want those drugs in the cancer, you don't want them just everywhere in the body." #WilliamsCancer #Cancer #Oncology #Tumors #Immunotherapy #PulseElectricField #ImmuneSystem #TargetingTumors WilliamsCancerInstitute.com Download the transcript here

May 5, 2025 • 23min
Next-Generation Full-Spectrum Botanical Medicines with Joel Stanley Ajna Biosciences
Joel Stanley is the CEO of Ajna Biosciences, a company developing the next generation of botanical medicines. These full-spectrum drugs, derived from plants and fungi, are regulated and approved through the FDA, unlike dietary supplements. Lead drug candidates are targeting autism, generalized anxiety disorder, and PTSD. With expertise in cultivating and scaling the production of botanical raw materials, Ajna is creating a sustainable model compared to wild-harvested botanicals. Joel explains, "It's no secret that before about a hundred years ago, all of our medicines were botanical medicines, or mostly coming from plants, or maybe mushrooms. And in the last century, as we developed Western medicine - modern medicine - the drug approval process started to learn how to synthesize molecules and isolate molecules from nature. So we started to step completely away from plant medicine and into a synthetic pharmaceutical landscape. The FDA fairly recently started allowing botanical drugs. So what that means is that it's full-spectrum medicines coming from the given root, shrub, leaf, flower, or mushroom. Those would be botanical drugs. So botanical drugs are not single-compound botanically derived drugs, which make up about 20% of our pharmaceuticals. They're a full-spectrum plant extract, a botanical drug from a regulatory standpoint." "So, plant-based therapeutics can mean dietary supplements that do not go through clinical trials. They're not legally prescribed by doctors and generally not covered by insurance. Whereas botanical drugs go through the FDA drug approval process, rigorous clinical trials against placebo control to become FDA approved, covered by insurance, and legally prescribable. So that's really what sets what we're doing, creating botanical drugs, apart from what people have considered plant medicine this last century." "Our most advanced drug in our pipeline is called AJA001, and it's very special to me because I've been basically working on this drug for more than 15 years. It's made in partnership with my previous company. I was the first CEO of a company called Charlotte's Web, which was really the first, and it's still the largest CBD brand out there. It was everything we learned at Charlotte's Web that kind of prompted me to start Ajna BioSciences four years ago. And that first drug is made from full-spectrum hemp, so it is CBD dominant, and it does have other cannabinoids, such as THC, as well as other minor cannabinoids. It also has certain terpenes." #AjnaBiosciences #BotanicalMedicine #PlantBasedTherapeutics #PharmaInnovation #DrugDevelopment #NaturalMedicine #BioTech ajnabiosciences.com Download the transcript here

May 1, 2025 • 19min
Role for AI-Enhanced Screening in Early Detection of Breast Cancer with Dana Brown iCAD
Dana Brown serves as President, CEO, and Chairman of the Board at iCAD Inc., which has developed a next-generation approach that leverages advancements in AI and imaging technology to improve the accuracy and efficiency of breast cancer screening. This technology can help reduce unnecessary biopsies and additional tests while more accurately identifying cancers that need immediate attention. The concerning trend of rising breast cancer in younger women highlights the importance of early detection and personalized care plans. Dana explains, "Literally, iCAD's first FDA-cleared product in a first-generation AI was around 2002. So it's been well over 20 years. We're now on our fourth generation. So, yes, you're very accurate in describing this as a next-generation approach. So, not only has imaging technology improved over the past 20 years, but artificial intelligence has also improved. We continue to leverage the latest in artificial intelligence technology, how the artificial intelligence can be trained and learn, and a broad base of researchers that help us develop the solution. So you have new minds, new ways to think about solving the problem, and new technology that can be used to solve the problem. Then, there is a new underlying screening technology that gets better and better at clearer imaging." "The American Cancer Society reports that if we can catch a breast cancer very early in stage one, then the likelihood of, I'll say surviving breast cancer is 99%, so very, very high. So the earlier we can catch a breast cancer, the less invasive and costly and length of time the treatments can be. There are more options for those patients as well as the likelihood of a positive outcome, being able to again, have no further evidence of the disease is increased." #iCAD #BreastCancer #BreastCancerScreening #Radiology #CancerDetection #BreastBiopsies #Mammogram #WomensHealth #MedAI icadmed.com Download the transcript here

Apr 30, 2025 • 27min
Early Detection of Alzheimer’s Protein Biomarker with Home Blood Test with Dr. Rany Aburashed Neurogen Biomarking
Dr. Rany Aburashed, CEO and Founder of Neurogen Biomarking, is using a blood-based biomarker looking at p-tau 217 to detect early signs of Alzheimer's disease, up to 8-10 years before the onset of clinical symptoms. The company has built an ecosystem to provide patients with a comprehensive health assessment with an at-home blood test, cognitive testing, access to neurologists, and education on lifestyle changes that can support a good quality of life. Their mission is to take a proactive rather than the current reactive approach to diagnosing and slowing the progression of cognitive decline. Rany explains, "The challenge for us, and this is what I saw from years of clinical practice and hospital management, is that a disease like Alzheimer's operates almost like a green light. Life is okay, you're having minor issues, but for the most part, you're moving along. Then suddenly you notice a sentinel event, which then becomes that red light, and now you have Alzheimer's dementia. And so the issue that is at the core of Alzheimer's is early detection. Is there a way for us to detect things earlier and, in turn, provide patients with an opportunity to take control of their dementia and make the necessary changes in treatments?" "In the current setting, the way that we do it in the United States and around the world is really reactive and it is too late by the time your mother or father is developing cognitive complaints. It's very easy to ignore the early stages of it because you can function for three to five years without really anything dramatic happening. So suddenly, when that dramatic instance occurs, for example, you leave the stove on, or you get lost driving back to your house, something that's very obviously outside of the normal, that might trigger you to say, "Let's get Mom checked." "At launch, our focus is on using the biomarker called p-tau 217. This biomarker can be detected now with more technologies in the blood at microscopic levels, and we couldn't do that effectively 10 or 15 years ago. That science has caught up, and the technology has caught up to a point that now, even 8 to 10 years before any significant clinical symptoms occur, we're able to detect if this protein is elevated. Now, if this protein is elevated, depending on the assay that we use, it's about 93%-97% sensitive for potentially developing Alzheimer's long-term. So it's a good protein to use as a triage protein." #NeurogenBiomarkings #Biomarkers #BloodBiomarkers #Alzheimers #AlzheimersDisease #CognitiveDecline #Dementia #EarlyDetection #Neurologists NeurogenBiomarking.com Download the transcript here

Apr 29, 2025 • 21min
Impact of Integrating AI into Behavioral Health Workflow and Patient Engagement with Ram Krishnan Valant
Ram Krishnan, CEO of Valant, uses AI to make mental health care more accessible through their practice management and patient engagement platforms designed specifically for mental health providers. AI is applied to improve administrative efficiency, address billing and compliance, and drive successful patient outcomes. New solutions are needed due to the growing patient population for mental health services and the potential of advanced therapeutics that are transforming the behavioral health environment, where demand is outpacing the supply of mental health care providers. Ram explains, "If I took a step back, AI - let's describe what AI is across a practice. Multiple functional verticals exist within a practice, including marketing. A team is trying to acquire the right type of patients. There's your administrative vertical, if you will, which is just making sure you're running the business well. You have your clinical vertical, which is the time the clinician, prescriber, psychiatrist, and practitioner spend with the patient. There's billing, making sure you're getting paid for all this work, and there's compliance along the way. And each of these verticals has the potential to have an increased efficiency, first and foremost, by AI. Secondly, behind it are improved outcomes." "Yes, I think we are getting into a wild realm of possibilities for our application of AI. I think what we are making in our systems is a cautious and practical, pragmatic approach of working our way through the functions that I laid out, and then the goals in terms of efficiency. I think there is a wide range of potential here with AI. When people think of AI in mental health, they immediately think of an AI avatar of some kind that you can converse with and becomes a replacement for the therapist and a replacement for the understanding and awareness of everything. From the words you're choosing to the changes in your vocal modulation to the facial expressions on your face. Putting that all through the analytics to come back and assess risk of things like you said, suicide ideation or violence, potential violence. I think those are much later-term applications. There has to be a purpose behind that." #Valant #BehavioralHealth #MentalHealth #PatientEngagement #PracticeManagement valant.io Download the transcript here

Apr 28, 2025 • 18min
Organ Preservation Technology Transforming Organ Transplantation with Jaya Tiwari XVIVO
Jaya Tiwari, Senior Vice President of Clinical and Regulatory Affairs at XVIVO, which is focused on improving organ preservation for transplantation. Current organ preservation methods using ice coolers limit the time and distance organs can be transported. XVIVO's perfusion technology can significantly extend the preservation time of hearts, kidneys, livers, and lungs, providing hospitals and transplant centers access to more viable organs. The company is passionate about increasing organ availability to give more patients access to life-saving transplants. Jaya explains, "I take it back to 1967 when the first heart transplant was performed in Cape Town, and the way that the heart was preserved and transported in essentially an ice box. The standard of care for the preservation of organs is still an ice or an ice cooler with ice. So, this decreases metabolic activities. So, to try to preserve the organs so that you can get them from the donor to the recipient, the problem is that the organs are not viable for a very long time, and they start to degrade very quickly. That really limits the amount of time that the organs can be on ice, transported from the donor to the recipient hospital. Because of that logistical complexity, a lot of organs are ultimately not transplanted." "There have been some preclinical studies that we've done that have shown viability of the heart tissue for up to 24 hours. But what I think is probably the most remarkable example that we've seen is that the universities in Paris have put together something called an investigator-initiated study, where they actually were able to transport a donor heart from the French West Indies to Paris for transplant. That was about 12 hours that the heart was in transport and using the device. So that's remarkable because that essentially tripled the standard preservation time for hearts. Now, in the US, we have a clinical trial where we're currently seeking approval from the FDA that it's safe and effective to use this device for up to 12 hours." #XVIVO #HealthcareInnovation #LifeSavingTechnology #PatientOutcomes #OrganTransplantation #OrganTransplants xvivogroup.com Download the transcript here

Apr 25, 2025 • 19min
Interoperability Breaks Down Healthcare Silos to Facilitate Value-Based Care with Brian Drozdowicz PointClickCare
Brian Drozdowicz, Senior VP and General Manager for Acute and Payer at PointClickCare, provides a platform using predictive analytics and AI for data sharing and collaboration across healthcare stakeholders. Interoperability has been an ongoing challenge due to the lack of standards and clear governance to support data sharing. The shift to value-based care drives the need for more access to patient data to improve patient outcomes, facilitate care transitions, and reduce readmissions and costs. Brian explains, "PointClickCare has been a player in the market for quite some time. We're best known for the market-leading senior care EHR that we've had in market for 20-plus years. I run a business unit that sits by the side of that. We refer to that as the acute and payer business. And ultimately, this additional business and value proposition to the market operates the largest care collaboration network, sharing healthcare data across all the different stakeholders, hospitals, health plans, ambulatory clinics, community providers, and connecting is our core business. So we're ultimately in the business of sharing data and doing that safely, securely in a trusted way." "There are a lot of ways of driving adoption and sharing data at scale. I'd call out a couple of key areas in which we've seen a lot of progress in recent years. First is having well-established technology standards that safely and securely transmit that data. Number Two is having to share that data. So, otherwise, it's a bunch of data flowing back and forth just for the sake of data. And that doesn't solve anything with value-based care. Putting a set of guardrails in place requires providers and payers to work together with this data." #PointClickCare #HealthcareData #Interoperability #MedAI #DataSilos #ValueBasedCare #VBC pointclickcare.com Download the transcript here

Apr 24, 2025 • 21min
Real-Time Nudges to Physicians Help Reduce Clinical Waste in Hospitals with G. T. LaBorde IllumiCare
G.T. LaBorde, CEO and Co-Founder of IllumiCare, focuses on reducing hospital clinical waste. Doctors often make decisions about tests, medications, and procedures without knowing the actual cost to the hospital and the patient. The IllumiCare platform aims to nudge doctors to make cost-effective decisions without compromising the quality of patient care by providing cost information and clinical guidance at the point of care. Another benefit is the reduction in overtesting and overprescribing, supporting efforts to improve patient safety.. G.T. explains, "When doctors make decisions about what test to order and what medications to prescribe, particularly in the inpatient setting, they have no idea what the cost is. They don't know the relative cost of one drug or another, and it's not a knock on doctors. It's very difficult to know because there are, in our average hospital across hundreds of hospitals, something like 2,000 different medications on the formulary that are available to order if you're a provider." "We self-impose a limit, on average, taking only 60 seconds of a provider's attention a day. We calculate when we nudge somebody, when we present something in their workflow, how much time is it on the screen? And it comes down to 60 seconds a day of attention that we take. So we take great pride in how much technology we use to figure out when not to say something or not. We try to figure out the person most likely to take action, and is this information germane to this person for this patient, such that there's a high probability they'll take action? And we measure how frequently people take the action we recommend, and it's several times higher than similar alerts within the electronic medical record." #IllumiCare #ValueBasedCare #VBC #HealthcareInnovation #ClinicalDecisionSupport #HealthIT #HospitalIT #EHR illumicare.com Download the transcript here
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.